New combo treatment targets Post-Surgery binge eating

NCT ID NCT04599478

Ongoing Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a combination of medication (naltrexone/bupropion, also known as Contrave) and behavioral weight-loss counseling can help people who experience loss-of-control eating after bariatric surgery. About 160 adults who had gastric bypass or sleeve gastrectomy about six months ago will receive either the medication, counseling, both, or a placebo. The goal is to reduce binge-eating episodes and improve weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Naltrexone and Bupropion (Contrave) pills
What this could lead to: If successful, this could provide an effective treatment option for people who struggle with loss-of-control eating after bariatric surgery, helping them achieve better weight loss.
What could go wrong: This is an early-stage study (Phase 2/3) with only 160 participants, so results may not apply to everyone. The medication can cause side effects like nausea, headache, and insomnia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOSS-OF-CONTROL EATING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

binge eating disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOSS-OF-CONTROL EATING OBESITY & OVERWEIGHT

Contacts and locations

Locations

Yale Department of Psychiatry

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.